News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Kami Maddocks, MD, Ohio State University Medical Center

Articles by Kami Maddocks, MD, Ohio State University Medical Center

Closing Thoughts on Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Improving Outcomes in Patients With R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Emerging Therapies for R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Safety and Efficacy of Oral Agents in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

CD19-Directed Therapies for Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

CAR T in R/R DLBCL: Safety and Patient Selection

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

ASCO 2020 Data: CAR T in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Role of CAR T-cell Therapy in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Treatment in Transplant-ineligible R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Prognosis of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Standard of Care for Treatment of DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Latest Updated Articles

Safety and Efficacy of Oral Agents in R/R DLBCL
Published: July 15th 2020 | Updated:
Emerging Therapies for R/R DLBCL
Published: July 15th 2020 | Updated:
CD19-Directed Therapies for Treatment of R/R DLBCL
Published: July 15th 2020 | Updated:
ASCO 2020 Data: CAR T in R/R DLBCL
Published: July 15th 2020 | Updated:
Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T
Published: July 15th 2020 | Updated:
Standard of Care for Treatment of DLBCL
Published: July 15th 2020 | Updated:

Trending on OncLive

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma

Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma